Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells
© Wang et al; licensee BioMed Central Ltd. 2011
Received: 8 March 2011
Accepted: 18 May 2011
Published: 18 May 2011
There is evidence from epidemiological and in vitro studies that the biological effects of testosterone (T) on cell cycle and survival are modulated by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in prostate cancer. To investigate the cross talk between androgen- and vitamin D-mediated intracellular signaling pathways, the individual and combined effects of T and 1,25(OH)2D3 on global gene expression in LNCaP prostate cancer cells were assessed.
Stringent statistical analysis identifies a cohort of genes that lack one or both androgen response elements (AREs) or vitamin D response elements (VDREs) in their promoters, which are nevertheless differentially regulated by both steroids (either additively or synergistically). This suggests that mechanisms in addition to VDR- and AR-mediated transcription are responsible for the modulation of gene expression. Microarray analysis shows that fifteen miRNAs are also differentially regulated by 1,25(OH)2D3 and T. Among these miR-22, miR-29ab, miR-134, miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are down regulated. A number of genes implicated in cell cycle progression, lipid synthesis and accumulation and calcium homeostasis are among the mRNA targets of these miRNAs. Thus, in addition to their well characterized effects on transcription, mediated by either or both cognate nuclear receptors, 1,25(OH)2D3 and T regulate the steady state mRNA levels by modulating miRNA-mediated mRNA degradation, generating attenuation feedback loops that result in global changes in mRNA and protein levels. Changes in genes involved in calcium homeostasis may have specific clinical importance since the second messenger Ca2+ is known to modulate various cellular processes, including cell proliferation, cell death and cell motility, which affects prostate cancer tumor progression and responsiveness to therapy.
These data indicate that these two hormones combine to drive a differentiated phenotype, and reinforce the idea that the age dependent decline in both hormones results in the de-differentiation of prostate tumor cells, which results in increased proliferation, motility and invasion common to aggressive tumors. These studies also reinforce the potential importance of miRNAs in prostate cancer progression and therapeutic outcomes.
Prostate cancer is the most commonly diagnosed non-cutaneous cancer in American males and is the second leading cause of cancer-related deaths in males in North America . Androgens, including testosterone (T) and its active metabolite 5α-dihydrotestosterone (5α-DHT), are important for the development and growth of early stage prostate tumors and exert their effects via androgen receptor (AR) [2–4]. Androgen ablation has been one of the mainstays for the treatment of early stage, organ-confined prostate cancer along with surgery and radiation therapy.
Several epidemiological studies have suggested that adequate levels of vitamin D are critical for the prevention of various solid tumors, including breast, ovarian and colon cancers [5, 6]. The risk of developing and dying of these cancers appears to be inversely correlated with sun exposure, and/or vitamin D status, suggesting that vitamin D has chemopreventive properties . Some studies have also suggested that vitamin D may play a role in prostate cancer prevention [8, 9], but the data are less convincing than in other tumors and several recent meta-analyses have found weak or no associations between serum 25-hydroxyvitamin D3 (25(OH)2D3) levels and tumor incidence and progression [10–13]. In addition, the effects of 1,25(OH)2D3 on tumor growth in the TRAMP, LPB-Tag transgenic and Nkx3.1;PTEN mutant mouse models of prostate cancer have produced conflicting results [14–16]. However, a variety of in vitro studies demonstrate that 1,25(OH)2D3 or its non-calcemic analogs (EB1089; CB 1093; Gemini analogs) induce apoptosis in a variety of prostate cancer cell lines including LNCaP, LNCaP C4-2, ALVA-3, LAPC-4, DU-145 and PC-3 [17–20]. These effects appear to occur through a combination of G0/G1 cell cycle arrest, apoptosis, differentiation and inhibition of angiogenesis [21–25]. In contrast, other studies have shown that 1,25(OH)2D3 induces cell cycle arrest but not apoptosis [26–28]. These disparate effects of 1,25(OH)2D3 on prostate tumor biology appear to be dictated predominantly by the androgen status of the mice  or the level of androgen in the culture medium [17, 29], suggesting that in prostate cancer, there may be significant cross talk between androgen-mediated growth and vitamin D3-mediated cell cycle arrest and differentiation which may influence tumor initiation and progression, and impact tumor growth and affect subsequent therapeutic intervention .
MicroRNAs (miRNAs) are a class of small non-coding, single-stranded RNAs that post-transcriptionally modulate the steady state levels of mRNA by targeting the 3' untranslated regions (3'UTR) of mRNAs. Recent studies have found that aberrant miRNA expression is closely associated with prostate cancer initiation and progression [30, 31]. Several miRNAs that possess either oncogenic (miR-221/222, miR-21, miR-125b) [32–36] or tumor suppressor roles (miR-34 cluster, miR-146a, miR-200c) [37, 38] have been identified in prostate cancer and some of these are associated with the castration resistant phenotype , or hormone-independent growth of prostate cancer . Neither the effect of 1,25(OH)2D3 on miRNA levels in prostate cancer cell lines, nor the interaction with androgen signaling to modulate mRNA and miRNA transcription have been investigated. However, the importance of a regulatory loop involving miR-106b and p21 mRNA which is modulated by 1,25(OH)2D3 in non malignant prostate cells has recently been described . The experiments described in this manuscript examine effects of testosterone and 1,25(OH)2D3, administered alone or in combination, on the mRNA and miRNA expression in LNCaP cells and demonstrate that cross talk between VDR- and AR-mediated signaling significantly influences the biology of prostate cancer cells. Using concurrent microarray analyses in LNCaP cells of both miRNA and mRNA, we have found that androgen-mediated transcription of both mRNA and miRNA is enhanced by 1,25(OH)2D3, either additively or synergistically, highlighting the extensive cross talk between the two receptors. Many of the gene targets of T and 1,25(OH)2D3 have significant clinical relevance. The data demonstrate that while androgens may play a central role in the development of prostate cancer, declining T levels common in older patients may play a significant role in tumor progression, particularly in patients who are also vitamin D deficient.
Biological Response of LNCaP cells to T and 1,25(OH)2D3
Effect of T and 1,25(OH)2D3 on gene expression in LNCaP cells
Gene Set Enrichment Analysis of representative gene sets identified as significantly enriched after 1,25(OH)2D3 treatment in the presence of androgen in LNCaP cells.
T & D
Anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process
Elevation of cytosolic calcium ion concentration
qPCR Validation of Microarray Analyses
It is well established that ligand-activated AR and VDR bind to cognate response elements (ARE and VDRE respectively) to modulate gene transcription and thus the coordination between T and 1,25(OH)2D3 may be the consequence of receptor mediated transcription by both AR and VDR. While in silico searches for ARE and VDREs within 10 kb upstream or downstream of the structural genes shown to be modulated by T or 1,25(OH)2D3 or both, demonstrate that many of the genes have canonical response elements in their promoters (additional file 6), nearly 50% of the genes identified in the expression microarray analysis appear to lack functional hormone response elements (either ARE or VDRE or both) in their promoters (additional file 6). For instance, genes that have previously been documented to be only 1,25(OH)2D3 inducible and/or contain VDRE at their promoters (KCNMB4, CXCR4) are also modulated by T (Figures 5 and additional file 4). Furthermore, genes such as CDC20 that lack both VDREs and AREs are down regulated by 1,25(OH)2D3 and T together while neither steroid alone has significant effects on gene expression (Figures 4 and additional file 5). These data demonstrate that 1,25(OH)2D3 has distinct effects on the regulation of transcript levels and that for a significant proportion the genes, the effects of 1,25(OH)2D3 require the presence of T for maximal effect. Furthermore, it appears that in addition to modulating transcription of the responsive genes, T and 1,25(OH)2D3 modulate the stability of the transcripts via modulation of miRNA expression.
Effect of T and 1,25(OH)2D3 on miRNA expression
miRNAs differentially modulated by 1,25(OH)2D3 and T alone or in combination in LNCaP cells, identified by Agilent Human miRNA microarray v3.
T + 1,25(OH)2D3
In addition to the miRNAs identified from the microarray analysis, we have also assessed the effect of T and 1,25(OH)2D3 on miRNAs that have been reported to be deregulated in prostate cancer. The oncogenic miR-221, which has been reported to contribute to androgen-resistance phenotype is slightly down regulated by T and 1,25(OH)2D3 at 48 h, though the fold change is not statistically significant (additional file 8). Changes in the AR-inducible  and VDR-inducible  miR-125b are also not significant in LNCaP cells in this experimental paradigm (additional file 8). However, as already shown, the steady state levels of miR-21 are up regulated by T and 1,25(OH)2D3 in LNCaP cells with the highest fold-induction at 72 h in the presence of both hormones (Figure 7). This implies that the expression of miR-21 targets, such as PDCD4, may also be modulated by AR and VDR in LNCaP cells.
The data presented here demonstrate that both T and 1,25(OH)2D3 modulate the mRNA and miRNA profiles in LNCaP cells, and that the combination of the two hormones modulates a significantly larger cohort of transcripts than either hormone alone. In most cases, the effects of the two hormones are additive or synergistic. Since the predicted changes in the cohort of proteins present in the cells would be expected to influence the response to therapeutic agents, this raises questions regarding the interpretation of previous in vitro data describing the responsiveness of prostate cancer cell lines grown in the absence of these hormones.
The time frame we have chosen for the initial microarray experiments (48 h) and the times chosen for qPCR validation (24, 48 and 72 h) were selected based on previous experiments examining the induction of apoptosis in LNCaP cells by diverse agents including bicalutamide and Iejimalide . These time points will not discriminate between primary effects of T and 1,25(OH)2D3 on transcription and secondary effects which may be due to either the modulation of miRNA, and subsequent degradation of target mRNAs or cascading regulation of transcription of other genes. However, this time frame is appropriate to examine the effects of induced miRNAs on transcript stability.
Bioinformatic analysis demonstrates that T and 1,25(OH)2D3 alter the expression of genes associated with several relevant gene ontologies that clearly have the potential to significantly influence the biology of the tumor cells, their interaction with the tumor microenvironment and their response to therapeutic intervention. Perhaps the most important of these changes relate to the regulation of calcium ion homeostasis and cell cycle progression. One of the primary physiological roles of 1,25(OH)2D3 is to regulate calcium and phosphorus metabolism in bone. However, 1,25(OH)2D3 also plays an important role in cell cycle regulation in many cancers, including breast, ovarian and colon cancer, through its interaction with the VDR [6, 45–48]. In LNCaP cells, 1,25(OH)2D3 induces the expression of both voltage-gated (CACNG4) and non-voltage-gated (TRPV6) Ca2+ channels located on the plasma membrane. Though TRPV6 is primarily modulated by VDR, the full induction of ITPR1, annexin AII (ANXA2) and S100A10, major components of the TRPV6 auxiliary protein complex, requires the presence of both hormones, as does the induction of the highly Ca2+ sensitive PLC-δ3 (PLCD3). There is also a concurrent increase in ITPR1 in response to T and 1,25(OH)2D3 which has been shown to lead to increased signaling through the PI3K/AKT pathway . This suggests that in response to T and 1,25(OH)2D3, the production of IP3 will increase, triggering the release of Ca2+ from endoplasmic reticulum (ER) stores via ITPR1, leading to the activation of TRPV6 through S100A10, resulting in an influx of Ca2+ and augmenting intracellular Ca2+ levels. In addition, diacylglycerol, produced by PLC mediated cleavage of PIP2, may activate PKC, to further increase the activity of TRPV6 via phosphorylation . Together, these data suggest that the combination of T and 1,25(OH)2D3 elevates the intracellular Ca2+ level to establish a new homeostatic set point without inducing cell death. Since the induction of the execution phase of apoptosis in prostate cancer cells requires the elevation of intracellular free Ca2+ into the micromolar range , resetting the intracellular Ca2+ concentration closer to this threshold may render tumor cells more sensitive to apoptosis-inducing agents including doxorubicin, bicalutamide and radiation. It is well known that uncontrolled release of Ca2+ stores from the ER, for example in response to thapsigargin, initiates apoptosis via the activation of Ca2+-dependent caspases accompanied by release of cytochrome c through the mitochondrial permeability transition pore . It is therefore likely that a fine-tuned Ca2+ balance within the cellular compartments in prostate cancer cells occurs after treatment with 1,25(OH)2D3 and thus prevents Ca2+ overload in the mitochondria and maintains other Ca2+-dependent signaling, which may include the modulation of miRNA expression . Importantly, both T and 1,25(OH)2D3 appear to be required to establish the elevated homeostatic calcium levels. In this regard, the capacitative Ca2+ entry that has been shown to block the development of the apoptosis resistance phenotype such as that seen in Bcl-2 over-expressing LNCaP cells [54, 55] may be equivalent to the elevated homeostatic Ca2+ level induced by T and 1,25(OH)2D3, suggesting that adequate levels of the two hormones should also prevent the development of the apoptosis-resistant, or castration resistant, phenotype in prostate cancer.
Many of the changes in the steady state mRNA levels can be attributed to changes in transcriptional activity due to the presence of functional AREs and/or VDREs in the promoters of target genes. However, in silico searches suggests that the promoters of nearly 40% of the affected genes do not contain either response element. Both T and 1,25(OH)2D3 have been shown to induce rapid Ca2+ influx via store-operated Ca2+ (SOC) channels whose activities are mediated by membrane receptors (mVDR & mAR) and are related to the non-genomic action of AR and VDR [56–58]. In addition, the ligand-activated VDR can modulate transcription of some target genes through Sp-1 sites [59–61]. Therefore, it is likely that additional mechanisms are responsible for the extensive modulation seen in response to the two hormones.
As demonstrated here, T and 1,25(OH)2D3 cooperatively modulate a circumscribed group of miRNAs, which mediate mRNA degradation depending on the complementarity of the miRNA seed sequence to sequences within the 3'UTR of the transcript. While alterations in individual miRNAs are not as profound as those seen in the mRNA profiles, many of the miRNAs share identical seed sequences, which results in a cumulative effect on the target transcripts. In LNCaP cells, most of the miRNAs identified in this study are up regulated in response to T and 1,25(OH)2D3, including miR-21, miR-22, miR-29ab, miR-134 and miR-371-5p and miR-1207-5p. Both miR-21 and miR-29b have previously been shown to be induced by R1881 in LNCaP and LAPC-4 prostate cancer cells . Induction of these miRNAs results in substantial down regulation of several large cohorts of genes classified by GO. Thus, in addition to down regulating transcription through their cognate hormone response elements, T and 1,25(OH)2D3 can profoundly affect the stability of the transcripts encoding proteins that function in cell cycle control, cytoskeleton organization, and DNA damage repair among others. In this context, MYCBP, a positive regulator of c-Myc activity and a validated miR-22 target should be repressed by T and 1,25(OH)2D3, thus inhibiting c-Myc mediated transcription of E-box containing genes . In breast cancer cells, this correlates with suppressed cell proliferation and anchorage-independent growth suggesting that increased expression of miR-22 at 48 h in prostate tumor cells by T and 1,25(OH)2D3 may be partially responsible for cell cycle arrest and the prevention of tumor progression. In LNCaP cells miR-134 is very significantly up regulated by 1,25(OH)2D3 in the absence and presence of T. The role of miR-134 in prostate cancer has not been previously described, however the steady state level of miR-134 is modulated by members of the p53/p73/p63 family as part of a miRNA-tumor suppressor network . Thus, increased expression of miR-134 may further contribute to the activity of T and 1,25(OH)2D3 to suppress tumor growth.
While miR-21 was not identified in the microarray as a T and/or 1,25(OH)2D3 regulated miRNA, it was identified in the more informative qPCR analysis as a target of T and 1,25(OH)2D3, and the increases in the steady state level of miR-21 are significant after 48 h of treatment. Previous studies in breast and pancreatic cancer cell lines have suggested that over expression of miR-21 may lead to increased cell proliferation and decreased apoptosis through the targeted degradation of tumor suppressor protein PDCD4 [62, 65]. In prostate cancer cells, these effects would be anticipated to counteract the anti-proliferative effects of 1,25(OH)2D3, suggesting that not all interactions between AR- and VDR-mediated signaling are beneficial. Interestingly, neither of the other miRNAs that have been implicated in prostate tumor progression (miR-221 or miR-125b) is modulated by T nor 1,25(OH)2D3 in this in vitro model system. In addition to up regulating miRNAs that encode cell cycle regulatory proteins and calcium ion homeostasis, T and 1,25(OH)2D3 down regulate the expression of the oncomiR cluster, miR-17/92. These data suggest that miRNAs may play important roles in T- and 1,25(OH)2D3-induced cell cycle arrest in prostate cancer cells. The concurrent analysis of mRNA and miRNA expression has demonstrated that many of the combined effects of T and 1,25(OH)2D3 are modulated by a small cohort of 15 miRNAs that are additively or synergistically regulated by the two hormones. Since the majority of men diagnosed with prostate cancer are likely to be vitamin D insufficient , these data may have a profound impact on our understanding of the molecular mechanisms underlying the chemopreventive and chemotherapeutic effects of vitamin D3. Based on the data presented here, vitamin D deficiency is likely to render tumor cells more aggressive and less sensitive to chemotherapy. Given the trend toward "active surveillance" for men diagnosed with early stage prostate cancer, understanding the cross talk between the androgen- and vitamin D-mediated cellular effects may have a significant impact on the care of men in the period between diagnosis and the initiation of treatment. If these two signaling pathways interact in tumor tissue as demonstrated here, individual variations in dietary vitamin D and/or sun exposure, as well as differences in circulating T levels, may greatly influence the rate of prostate tumor growth and the sensitivity of prostate cancer to hormone and other chemotherapies. In this context, the age related decline in serum testosterone may also contribute to the progression of prostate cancer. Thus, maintaining serum testosterone and combined with supplementation of vitamin D may substantially slow disease progression for men diagnosed with very early stage cancer, extending the time between diagnosis and treatment.
LNCaP human prostate cancer cells, obtained from American Type Culture Collection (Rockville, MD), were grown in RPMI-1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% FBS (Sigma-Aldrich, St Louis, MO), 100 U/mL penicillin and 100 μg/mL streptomycin. Cells were maintained at 37°C in a humidified atmosphere of 95% air/5% CO2. For all the experiments performed in this study, with the exception of crystal violet assays, LNCaP cells were plated at a density of 1 × 106 cells per 150 cm2 dish for 48 h prior to treatment with 5 nM T (Sigma-Aldrich) and 100 nM 1,25(OH)2D3 (Sigma-Aldrich) alone or in combination. The steroids were dissolved in ethanol, and control cells were treated with the same volume of vehicle.
Crystal Violet Assay
LNCaP cells were seeded at 20,000 cells/well in 24 well plates for 24 h prior to treatment with 5 nM T and 100 nM 1,25(OH)2D3 alone or in combination. Cells were fixed with 2% glutaraldehyde in PBS for 20 min at room temperature followed by staining with 0.1% crystal violet (Sigma-Aldrich) for 30 min. The crystal violet stain was solubilized in 0.2% Triton X-100 in ddH2O for 30 min and the absorbance was read with Victor3V 1420 Multilabel Counter (PerkinElmer Inc, Waltham MA) at 590 nm. Three independent biological replicates were analyzed in triplicate.
LNCaP cells were treated with 5 nM T and 100 nM 1,25(OH)2D3 as described above. Cells treated with either vehicle (EtOH) or 100 μM bicalutamide serve as the negative and positive control, respectively. For cell cycle analysis, the cells were treated for 24, 48 and 72 h and harvested by trypsinization, followed by 90% ethanol permeabilization overnight at -20°C. Permeabilized cells were stained with 5 μg/mL propidium iodide (Sigma-Aldrich) in the presence of 0.015 U/mL RNase (Roche Applied Science, Indianapolis, IN) in PBS for 20 min at room temperature. Samples were analyzed within 3 h of labeling on BD™ LSR II Flow Cytometer (BD Biosciences, San Jose, CA). A minimum of 10,000 events were analyzed for each experimental condition. Three independent biological replicates for each treatment group were analyzed.
Apoptosis was analyzed using Apo-BrdU staining. Cells were harvested by trypsinization and fixed with 4% formaldehyde in PBS for 30 min on ice, followed by 70% ethanol permeabilization overnight at -20°C. Samples were enzymatically labeled with bromodeoxyuridine triphosphate in TdT reaction buffer (Br-dUTP, 2.5 mM cobalt chloride, and terminal transferase 24,000 U) for 1 h at 37°C to label the 3'-OH ends of fragmented DNA (Roche). DNA strand breaks were counterlabeled with FITC-conjugated anti-BrdU monoclonal antibody according to the manufacturer's directions (Phoenix Flow Systems, San Diego, CA). Cells were counterstained with 5 μg/mL propidium iodide for 30 min at room temperature. Samples were analyzed on BD™ LSR II Flow Cytometer (BD Biosciences) within 3 h of labeling and a minimum of 10,000 events were analyzed for each experimental condition. Three independent biological replicates for each treatment group were analyzed.
mRNA Microarray Analysis
Total RNA isolated from LNCaP cells was processed using standard protocols for Nimblegen arrays. Briefly 10 μg of total RNA was reverse transcribed to cDNA using oligo-dT primers and Superscript II (Invitrogen), converted to double stranded cDNA and Klenow labeled with Cy3-labeled random 9-mers before hybridization to Nimblegen-Human-HG18 4 × 72 microarrays at 42°C for 16 h using a Nimblegen Hybridization system. The arrays were washed and scanned on a Genepix 4000B scanner following which the data was extracted using NimbleScan software. Further data analysis was performed using GeneSpring GX10. The raw dataset is available as a curated dataset at GEO (SuperSeries GSE23815, SubSeries GSE17461). Three independent biological replicates for each treatment group were analyzed.
miRNA Microarray Analysis
Total RNA was processed and hybridized to Agilent Human miRNA microarrays using standard protocols. 100 ng of total RNA was dephosphorylated with calf intestinal phosphatase and end-labeled with Cy3-pCp by T4 RNA ligase prior to an overnight hybridization at 55°C onto Agilent Human miRNA v3 (Sanger release 12.0) microarrays. The arrays were washed and scanned on a high resolution GC2565CA Agilent Scanner using the manufacturer's recommended settings. The raw data was extracted using Agilent Feature Extraction software v10.1.1 and imported into GeneSpring GX10 for further analysis. The raw data is available as a curated dataset at GEO (SuperSeries GSE23815, SubSeries GSE23814).
qPCR Validation of Microarray Data
Changes in mRNA and miRNA identified by microarray were validated in independent biological replicates. LNCaP cells were plated and treated as previously described for 24, 48 and 72 h. Cells were harvested by trypsinization and total RNA (both mRNA and miRNA) was extracted using miRNeasy mini kit (Qiagen, Valencia, CA). Reverse transcription PCR reactions were performed with 1.5 μg total RNA using Taqman® Reverse Transcription Reagents (Applied Biosystems, Carlsbad, CA) to synthesize cDNA for mRNA expression analysis. The reaction mixture was incubated for 10 min at 25°C, 1 h at 37°C and 5 min at 95°C and kept at -20°C until further analysis. qPCR probes for each gene were designed using Primer-Blast (National Center for Biotechnology Information) with default settings and synthesized by Integrated DNA Technologies (Coralville, IA). The list of primers for each gene is available in additional file 9. SYBR Green reactions with SYBR® Green PCR Master Mix (Applied Biosystems) were analyzed using the ABI 7900HT Fast Real-Time PCR System (Applied Biosystems): 50°C for 2 min, 95°C for 10 min, 95°C for 15 sec and 60°C for 1 min, repeated for 40 cycles. Relative expression levels of each gene in real time were analyzed using the 2-ΔΔCT method  and presented as ratio relative to the expression of the housekeeping gene GAPDH. For miRNA expression analysis, 10 ng total RNA were used to make cDNA with TaqMan® MicroRNA Reverse Transcription Reagents (Applied Biosystems). The reaction mixture was incubated for 30 min at 16°C, 30 min at 42°C and 5 min at 85°C and kept at -20°C until further analysis. TaqMan® MicroRNA Assays were used to evaluate miRNA expression according to manufacturer's protocol. TaqMan reactions were analyzed using the ABI 7900HT Fast Real-Time PCR System: 95°C for 10 min, 95°C for 15 sec and 60°C for 60 sec repeated for 40 cycles. Relative expression levels of each miRNA in real time were analyzed using the 2-ΔΔCT method with U6 snRNA as the reference control. Each sample was replicated twice from three independent sets of RNA preparations. Results are tabulated as mean ± SD and presented as fold change after transformation to show divergence from no effect (zero fold change).
Statistical Analysis of Microarray Data
For mRNA microarray analysis in GeneSpring GX10, the gene list was filtered to exclude entities which showed low signal values across all samples (i.e bottom 20th percentile). Statistically significant genes from each expression profile were selected using one-way ANOVA (p ≤ 0.05). The multiple testing correction Benjamini and Hochberg false discovery rate (FDR) (p-value <0.05) was integrated within each test. A fold change cut-off at 1.5 fold was implemented to generate the final list of differentially expressed genes. Genes passing the statistical tests were further assigned into their gene ontology (GO) grouping using DAVID Bioinformatics Resources v6.7 (NIAID) with the default setting, essentially as previously described . Significantly regulated and enriched GO groups were selected for qPCR analysis.
For miRNA microarray analysis, the raw data was imported into GeneSpring GX10, log2 transformed, normalized to the 75th percentile following which the entity list was filtered to exclude probes that showed low signal values across all treatment groups (i.e. bottom 20th percentile). This list was further filtered to only include entities that were marked "present;' or "marginal" in all 3 replicates for at least one of the 4 treatment groups. Entities with fold changes greater than 2.0 were considered significant when p < 0.05 using one-way ANOVA with Benjamini-Hochberg FDR post-test. Targets of miRNAs that passed the statistical test were identified using TargetScan Human v5.1 from Whitehead Institute for Biomedical Research. Gene targets whose mRNA expression levels were inversely proportional to the corresponding miRNA expression levels were considered concordant and were further analyzed for their enrichment in Gene Ontology grouping.
The research presented in this manuscript was supported by an operating grant from the USPHS (RO1 CA101114-04). The authors would like to thank David Frank and Marcy Kuentzel for excellent technical help with the microarray experiments; and Dr. Andrew Reilly for his help and insights into the analysis of the microarray data.
- Surveillance Epidemiology and End Results Web., http://seer.cancer.gov
- Lamont KR, Tindall DJ: Androgen regulation of gene expression. Adv Cancer Res. 2010, 107: 137-162.View ArticlePubMed
- Vis AN, Schroder FH: Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int. 2009, 104: 438-448. 10.1111/j.1464-410X.2009.08695.xView ArticlePubMed
- Vis AN, Schroder FH: Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase. BJU Int. 2009, 104: 1191-1197. 10.1111/j.1464-410X.2009.08743.xView ArticlePubMed
- Giovannucci E: Expanding roles of vitamin D. J Clin Endocrinol Metab. 2009, 94: 418-420. 10.1210/jc.2008-2695View ArticlePubMed
- Thorne J, Campbell MJ: The vitamin D receptor in cancer. Proc Nutr Soc. 2008, 67: 115-127. 10.1017/S0029665108006964View ArticlePubMed
- Garland CF, Gorham ED, Mohr SB, Garland FC: Vitamin D for cancer prevention: global perspective. Ann Epidemiol. 2009, 19: 468-483. 10.1016/j.annepidem.2009.03.021View ArticlePubMed
- Schwartz GG, Skinner HG: Vitamin D status and cancer: new insights. Curr Opin Clin Nutr Metab Care. 2007, 10: 6-11.PubMed
- Tseng M, Breslow RA, DeVellis RF, Ziegler RG: Dietary patterns and prostate cancer risk in the National Health and Nutrition Examination Survey Epidemiological Follow-up Study cohort. Cancer Epidemiol Biomarkers Prev. 2004, 13: 71-77. 10.1158/1055-9965.EPI-03-0076View ArticlePubMed
- Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC: Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control. 2010, 21: 1297-1303. 10.1007/s10552-010-9557-yPubMed CentralView ArticlePubMed
- Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN: Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer. 2010, 46: 932-936. 10.1016/j.ejca.2009.12.030PubMed CentralView ArticlePubMed
- Rhee HV, Coebergh JW, Vries ED: Sunlight, vitamin D and the prevention of cancer: a systematic review of epidemiological studies. Eur J Cancer Prev. 2009
- Yin L, Raum E, Haug U, Arndt V, Brenner H: Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol. 2009, 33: 435-445. 10.1016/j.canep.2009.10.014View ArticlePubMed
- Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA: Characterization of Vitamin D insensitive prostate cancer cells. J Steroid Biochem Mol Biol. 2007, 103: 712-716. 10.1016/j.jsbmb.2006.12.008PubMed CentralView ArticlePubMed
- Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N: Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin Cancer Res. 2006, 12: 5895-5901. 10.1158/1078-0432.CCR-06-1039View ArticlePubMed
- Mordan-McCombs S, Brown T, Wang WL, Gaupel AC, Welsh J, Tenniswood M: Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status. J Steroid Biochem Mol Biol. 2010, 121: 368-371. 10.1016/j.jsbmb.2010.03.062PubMed CentralView ArticlePubMed
- Murthy S, Agoulnik IU, Weigel NL: Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005, 64: 362-372. 10.1002/pros.20251View ArticlePubMed
- Oades GM, Dredge K, Kirby RS, Colston KW: Vitamin D receptor-dependent antitumour effects of 1, 25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int. 2002, 90: 607-616. 10.1046/j.1464-410X.2002.02964.xView ArticlePubMed
- Saito T, Okamoto R, Haritunians T, O'Kelly J, Uskokovic M, Maehr H: Novel Gemini vitamin D(3) analogs have potent antitumor activity. J Steroid Biochem Mol Biol. 2008, 112: 151-156.PubMed CentralView ArticlePubMed
- Washington MN, Kim JS, Weigel NL: 1alpha, 25-dihydroxyvitamin D(3) inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G(1) arrest. Prostate. 2010
- Bao BY, Yao J, Lee YF: 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis. 2006, 27: 1883-1893. 10.1093/carcin/bgl041View ArticlePubMed
- Ben Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ: 1alpha, 25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 2007, 6: 1433-1439. 10.1158/1535-7163.MCT-06-0677View ArticlePubMed
- Jiang F, Bao J, Li P, Nicosia SV, Bai W: Induction of ovarian cancer cell apoptosis by 1, 25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem. 2004, 279: 53213-53221. 10.1074/jbc.M410395200View ArticlePubMed
- Kizildag S, Ates H, Kizildag S: Treatment of K562 cells with 1, 25-dihydroxyvitamin D(3) induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCL(XL), and p21. Ann Hematol. 2009
- Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE: 1 alpha, 25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 2000, 87: 214-220.View ArticlePubMed
- Campbell MJ, Koeffler HP: Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst. 1997, 89: 182-185. 10.1093/jnci/89.3.182View ArticlePubMed
- Miller GJ, Stapleton GE, Hedlund TE, Moffat KA: Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha, 25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res. 1995, 1: 997-1003.PubMed
- Zhuang SH, Burnstein KL: Antiproliferative effect of 1alpha, 25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology. 1998, 139: 1197-1207. 10.1210/en.139.3.1197PubMed
- Weigel NL: Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutr Rev. 2007, 65: S116-S117. 10.1301/nr.2007.aug.S116-S117View ArticlePubMed
- Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008, 68: 6162-6170. 10.1158/0008-5472.CAN-08-0144PubMed CentralView ArticlePubMed
- Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67: 6130-6135. 10.1158/0008-5472.CAN-07-0533View ArticlePubMed
- Li T, Li D, Sha J, Sun P, Huang Y: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 2009, 383: 280-285. 10.1016/j.bbrc.2009.03.077View ArticlePubMed
- Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH: miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009, 69: 7165-7169. 10.1158/0008-5472.CAN-09-1448PubMed CentralView ArticlePubMed
- Sun T, Yang M, Kantoff P, Lee GS: Role of microRNA-221/-222 in cancer development and progression. Cell Cycle. 2009, 8: 2315-2316. 10.4161/cc.8.15.9221View ArticlePubMed
- Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M: An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA. 2007, 104: 19983-19988. 10.1073/pnas.0706641104PubMed CentralView ArticlePubMed
- Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW: miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate. 2011, 71: 538-549. 10.1002/pros.21270PubMed CentralView ArticlePubMed
- Lin SL, Chiang A, Chang D, Ying SY: Loss of mir-146a function in hormone-refractory prostate cancer. RNA. 2008, 14: 417-424. 10.1261/rna.874808PubMed CentralView ArticlePubMed
- Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB: MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther. 2008, 7: 1288-1296. 10.4161/cbt.7.8.6284View ArticlePubMed
- Thorne JL, Maguire O, Doig CL, Battaglia S, Fehr L, Sucheston LE: Epigenetic control of a VDR-governed feed-forward loop that regulates p21(waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res. 2011, 39: 2045-2056. 10.1093/nar/gkq875PubMed CentralView ArticlePubMed
- Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D: Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate. 2004, 59: 243-251. 10.1002/pros.20006View ArticlePubMed
- Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD: Molecular activity of 1, 25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol. 2004, 92: 131-141. 10.1016/j.jsbmb.2004.07.003View ArticlePubMed
- Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y: Large-scale in silico and microarray-based identification of direct 1, 25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005, 19: 2685-2695. 10.1210/me.2005-0106View ArticlePubMed
- Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T: MicroRNA regulates human vitamin D receptor. Int J Cancer. 2009, 125: 1328-1333. 10.1002/ijc.24459View ArticlePubMed
- Wang WL, McHenry P, Jeffrey R, Schweitzer D, Helquist P, Tenniswood M: Effects of Iejimalide B, a marine macrolide, on growth and apoptosis in prostate cancer cell lines. J Cell Biochem. 2008, 105: 998-1007. 10.1002/jcb.21898View ArticlePubMed
- Colston KW, Hansen CM: Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer. 2002, 9: 45-59. 10.1677/erc.0.0090045View ArticlePubMed
- Harris DM, Go VL: Vitamin D and colon carcinogenesis. J Nutr. 2004, 134: 3463S-3471S.PubMed
- Welsh J, Wietzke JA, Zinser GM, Smyczek S, Romu S, Tribble E: Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol. 2002, 83: 85-92. 10.1016/S0960-0760(02)00277-7View ArticlePubMed
- Zhang X, Nicosia SV, Bai W: Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr Cancer Drug Targets. 2006, 6: 229-244. 10.2174/156800906776842939View ArticlePubMed
- Khan MT, Wagner L, Yule DI, Bhanumathy C, Joseph SK: Akt kinase phosphorylation of inositol 1, 4, 5-trisphosphate receptors. J Biol Chem. 2006, 281: 3731-3737.View ArticlePubMed
- Al Ansary D, Bogeski I, Disteldorf BM, Becherer U, Niemeyer BA: ATP modulates Ca2+ uptake by TRPV6 and is counteracted by isoform-specific phosphorylation. FASEB J. 2010, 24: 425-435. 10.1096/fj.09-141481View ArticlePubMed
- Tombal B, Denmeade SR, Gillis JM, Isaacs JT: A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death Differ. 2002, 9: 561-573. 10.1038/sj.cdd.4400999View ArticlePubMed
- Szabadkai G, Duchen MR: Mitochondria: the hub of cellular Ca2+ signaling. Physiology (Bethesda). 2008, 23: 84-94.View Article
- Sonkoly E, Wei T, Pavez LE, Suzuki H, Kato M, Torma H: Protein kinase C-dependent upregulation of miR-203 induces the differentiation of human keratinocytes. J Invest Dermatol. 2010, 130: 124-134. 10.1038/jid.2009.294View ArticlePubMed
- Vanden Abeele F, Skryma R, Shuba Y, Van Coppenolle F, Slomianny C, Roudbaraki M: Bcl-2-dependent modulation of Ca(2+) homeostasis and store-operated channels in prostate cancer cells. Cancer Cell. 2002, 1: 169-179. 10.1016/S1535-6108(02)00034-XView ArticlePubMed
- Flourakis M, Prevarskaya N: Insights into Ca2+ homeostasis of advanced prostate cancer cells. Biochim Biophys Acta. 2009, 1793: 1105-1109. 10.1016/j.bbamcr.2009.01.009View ArticlePubMed
- Foradori CD, Weiser MJ, Handa RJ: Non-genomic actions of androgens. Front Neuroendocrinol. 2008, 29: 169-181. 10.1016/j.yfrne.2007.10.005PubMed CentralView ArticlePubMed
- Nakagawa K, Tsugawa N, Okamoto T, Kishi T, Ono T, Kubodera N: Rapid control of transmembrane calcium influx by 1alpha, 25-dihydroxyvitamin D3 and its analogues in rat osteoblast-like cells. Biol Pharm Bull. 1999, 22: 1058-1063.View ArticlePubMed
- Steinsapir J, Socci R, Reinach P: Effects of androgen on intracellular calcium of LNCaP cells. Biochem Biophys Res Commun. 1991, 179: 90-96. 10.1016/0006-291X(91)91338-DView ArticlePubMed
- Cheng HT, Chen JY, Huang YC, Chang HC, Hung WC: Functional role of VDR in the activation of p27Kip1 by the VDR/Sp1 complex. J Cell Biochem. 2006, 98: 1450-1456. 10.1002/jcb.20780View ArticlePubMed
- Huang YC, Hung WC: 1, 25-dihydroxyvitamin D3 transcriptionally represses p45Skp2 expression via the Sp1 sites in human prostate cancer cells. J Cell Physiol. 2006, 209: 363-369. 10.1002/jcp.20741View ArticlePubMed
- McGaffin KR, Chrysogelos SA: Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1, 25-dihydroxyvitamin D3 in breast cancer cells. J Mol Endocrinol. 2005, 35: 117-133. 10.1677/jme.1.01813View ArticlePubMed
- Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH: miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009, 69: 7165-7169. 10.1158/0008-5472.CAN-09-1448PubMed CentralView ArticlePubMed
- Xiong J, Du Q, Liang Z: Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene. 2010, 29: 4980-4988. 10.1038/onc.2010.241View ArticlePubMed
- Boominathan L: The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One. 2010, 5: e10615- 10.1371/journal.pone.0010615PubMed CentralView ArticlePubMed
- Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem. 2008, 283: 1026-1033.View ArticlePubMed
- Trump DL, Chadha MK, Sunga AY, Fakih MG, Ashraf U, Silliman CG: Vitamin D deficiency and insufficiency among patients with prostate cancer. BJU Int. 2009, 104: 909-914. 10.1111/j.1464-410X.2009.08531.xPubMed CentralView ArticlePubMed
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262View ArticlePubMed
- Huang dW, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009, 4: 44-57.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.